AG 013

Drug Profile

AG 013

Alternative Names: AG013; Lactococcus lactis expressing human trefoil factor 1; Lactococcus lactis secreting human trefoil factor 1; TFF1 - Intrexon; Trefoil factor 1 - Intrexon

Latest Information Update: 23 Nov 2016

Price : $50

At a glance

  • Originator ActoGeniX
  • Developer Intrexon Corporation
  • Class Bacteria; Peptides
  • Mechanism of Action Mucoprotein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Stomatitis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Stomatitis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Stomatitis

Highest Development Phases

  • Phase I Stomatitis

Most Recent Events

  • 21 Nov 2016 AG 013 receives Fast Track designation for Stomatitis [Topical,Liquid] (Prevention) in USA
  • 02 May 2016 Preclinical data released by Oragenics
  • 02 May 2016 Oragenics plans a phase II trial for Oral mucositis in USA and Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top